L-dopa therapy in Parkinson's disease.
D003693:Delirium; D003863:Depression; D004295:Dihydroxyphenylalanine / Q000008:administration & dosage / Q000009:adverse effects / Q000037:antagonists & inhibitors / Q000378:metabolism / Q000627:therapeutic use*; D006471:Gastrointestinal Hemorrhage; D006212:Hallucinations; D006801:Humans; D007024:Hypotension, Orthostatic; D008995:Monoamine Oxidase / Q000494:pharmacology; D009069:Movement Disorders / Q000188:drug therapy; D009325:Nausea / Q000139:chemically induced; D010300:Parkinson Disease / Q000188:drug therapy* / Q000473:pathology; D010640:Phenothiazines / Q000494:pharmacology; D010946:Plants, Medicinal; D011618:Psychotic Disorders; D011736:Pyridoxine / Q000494:pharmacology; D011926:Rauwolfia / Q000494:pharmacology; D014202:Tremor / Q000188:drug therapy; D014839:Vomiting / Q000139:chemically induced
D010640:Phenothiazines; D004295:Dihydroxyphenylalanine; D008995:Monoamine Oxidase; D011736:Pyridoxine